FNA cytology of lymphomas: useless or useful? Edneia Tani

Immunohistochemical differentiation of metastatic tumours

Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in

Update on Mesothelioma

November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

Practical Effusion Cytology

Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.

Ovarian tumors Ancillary methods

Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma

Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI,NIH DEPARTMENT OF HEALTH & HUMAN SERVICES

Frozen Section Diagnosis

Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The

Effusions: Mesothelioma and Metastatic Cancers

Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

A 70-year old Man with Pleural Effusion

Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or

A23: Oncologic Disease- Tumor Markers

A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of

Cytopathology Case Presentation #8

Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents

Diagnosis of Mesothelioma Pitfalls and Practical Information

Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com

Index. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, 272-275 5-HT, see Serotonin

A Acantholytic squamous cell carcinoma vs epithelioid angiosarcoma, 56-57 Acinic cell carcinoma of pancreas, 76-77 vs ductal adenocarcinoma, 74-75 vs islet cell tumor, 78-81 Adenomatoid tumor vs hemangioma,

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30

Pleural and Pericardial fluids a one year analysis

Pleural and Pericardial fluids a one year analysis Dr Olafsdottir Dr J Williams Department of Cytology, Llandough Hospital Contents Background Standards Aims/Questions Investigation group Results Conclusions

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

YOUR LUNG CANCER PATHOLOGY REPORT

UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7

OBJECTIVES By the end of this segment, the community participant will be able to:

Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa

- Slide Seminar - Endocrine pathology in non-endocrine organs Case 11 Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa Dept. of Pathology, Multimedica, Milan, Italy Dept. of Surgical and Morphological

The Diagnosis of Cancer in the Pathology Laboratory

The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens

4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma

Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer

How To Test For Cancer

Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland Diagnostic

Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!

Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor of

Lessons from a consultation practice

Pitfalls in the Application of Immunohistochemistry in Diagnostic Pathology Lessons from a consultation practice Kevin O. Leslie, MD Professor and Consultant Mayo Clinic Arizona Scottsdale, Arizona Presenter

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists

Cytology of Effusion Fluids. Cytology of Effusion Fluids. Types of Effusion Fluids. Anatomy. Causes of Effusions. Sampling of Effusion Fluids

Cytology of Effusion Fluids John W. Wong, MD, FRCPC Sunnybrook Health Sciences Centre Assistant Professor, Laboratory Medicine and Pathobiology Faculty of Medicine, University of Toronto November 10, 2012

How CanCer becomes critical in the claims

How CanCer becomes critical in the claims arena Cancer is a disease in which cells in your body grow in an uncontrolled way and form a lump called a tumour. In a healthy individual cells grow and reproduce

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.

Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)

Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy.

Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy. At the end of this session, the participant will be able to: 1. Describe the components of a flow cytometer 2. Describe the gating

Contents. 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1. 2. Head, Neck, Orbit and Salivary Glands... 12

Contents 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1 Complications 1 Fine Needle Aspiration Technique 1 Evaluation of FNAC Smear 4 Cell Morphology 4 Nucleus 4 Cytoplasm 6 Background

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia

FNA Cytology of Mediastinal Lesions. Presenters: Xiaoqi Lin, M.D., Ph.D. Ritu Nayar, M.D.

Disclosure information The speakers have no relationship that represents a possible conflict of interest with respect to the content of this presentation. FNA Cytology of Mediastinal Lesions Presenters:

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate

Cytology of Lymph Nodes

Indications Cytology of Lymph Nodes Lymph node enlargement That was easy Mary Anna Thrall Don Meuten Indications Lymph node enlargement Suspect metastasis Normal sized lymph nodes are Normal Do NOT aspirate

NEU IM PROGRAMM. LOXO Antikörper für die Immunhistochemie (alphabetisch nach Bezeichnung sortiert) Art.Code Artikelbezeichnung Typ Einsatz Einheit

A20002 Actin, Alpha-Smooth Muscle; Clone 1A4 monoklonal IHC 2 ml Ready-to-use A00002.0025 Actin, Alpha-Smooth Muscle; Clone 1A4 monoklonal IHC 25 ml Ready-to-use A00002 Actin, Alpha-Smooth Muscle; Clone

Report series: General cancer information

Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

Immunohistochemistry on cytology specimens from pleural and peritoneal fluid

Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Dr Naveena Singh Consultant Pathologist Bart health NHS Trust London United Kingdom Disclosures and Acknowledgements I have

How To Test For Cancer With A Blood Test

Histolab Products AB Eva Alströmer Jonas Falgén Helsingborg 7-8/10 2010 Table 1 Formalin Fixation Times and Estrogen Receptor Staining With 25 Minutes Antigen Retrieval Pretreatment Formalin Q-Score Difference

How To Diagnose And Treat A Tumour In An Effusion

Effusions of the Serous Cavities Annika Dejmek Professor/Consultant in Cytopathology Clinical Pathology; Department of Laboratory Medicine, Malmö, Lund University 5th EFCS Tutorial Trondheim 2012 Pleura

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

Pathology of lung cancer

Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

NEOPLASMS C00 D49. Presented by Jan Halloran CCS

NEOPLASMS C00 D49 Presented by Jan Halloran CCS 1 INTRODUCTION A neoplasm is a new or abnormal growth. In the ICD-10-CM classification system, neoplastic disease is classified in categories C00 through

Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.

Main Street Planning Group 180 East Main Street Suite 110 Patchogue, NY 11772 Tel: 631.647.4694 Fax: 631.647.4697 MainStreetPlanningGroup.com Presented by Ted Mageau Ted@MainStreetPlanningGroup.com Life

The develpemental origin of mesothelium

Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal

DIFFICULTIES IN THE PATHOLOGIC DIAGNOSIS OF LUNG CANCER Notice of Financial Disclosures (TV Colby MD) (Esp. in small biopsies) Personal Experience Thomas V. Colby, M.D. Mayo Clinic Arizona NONE This talk

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.

Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,

Carcinosarcoma of the Ovary

Carcinosarcoma of the Ovary A Rare Finding Presented By: Kathryn Kiely Anisa I. Kanbour School of Cytotechnology of the University of Pittsburgh Medical Center Pittsburgh, PA Patient History 55 year old

Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms

Clin Lab Med 27 (2007) 487 512 Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Fiona E. Craig, MD Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine,

Immunohistochemistry of soft tissue tumors

Immunohistochemistry of soft tissue tumors Immunohistochemistry Major advances : antigen retrieval techniques (HIER) sensitive detection systems numerous antibodies of good quality Standardization : automated

Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas

Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular

PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet

PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download

AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from

Neoplasms of the LUNG and PLEURA

Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:

PROTOCOL OF THE RITA DATA QUALITY STUDY

PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate

Cancer: DNA Synthesis, Mitosis, and Meiosis

Chapter 5 Cancer: DNA Synthesis, Mitosis, and Meiosis Copyright 2007 Pearson Copyright Prentice Hall, 2007 Inc. Pearson Prentice Hall, Inc. 1 What Is Cancer? Benign tumors do not invade surrounding tissue

General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014

General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention

The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin

Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,

THYROID CANCER. I. Introduction

THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in

SEROUS EFFUSION CYTOLOGY- A PRACTICAL APPROACH

Video Microsc copy Tutorial #20 Ashish Chandr ra, MD Disclosur re information The speaker has no relationship that representss a possible conflict of interest with respect to the content of this presentation.

GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE

Genomics in Medicine Series GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE Electron Kebebew, MD, FACS Outline To assess the change in thyroid cancer epidemiology

Diagnostic Challenge. Department of Pathology,

Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital

Diagnostic tests for tuberculous lymphadenitis: fine needle aspirations using tissue culture in mycobacteria growth indicator tube and tissue PCR

Asian Biomedicine Vol. 4 No. 5 October 2010; 787-792 Technical report Diagnostic tests for tuberculous lymphadenitis: fine needle aspirations using tissue culture in mycobacteria growth indicator tube

About B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic

RENAL CELL CARCINOMA EPIDEMIOLOGY

RENAL CELL CARCINOMA: THE 2012 ISUP VANCOUVER CLASSIFICATION David Grignon MD, Indiana University, Indianapolis, IN RENAL CELL CARCINOMA EPIDEMIOLOGY Siegel et al. CaA Cancer J Clin 63:11-30, 2013 1 EPITHELIAL

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What

Application of Molecular Diagnosis: Present and Future

Application of Molecular Diagnosis: Present and Future Dong Jun Lim, MD., PhD. Associate Professor Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary s Hospital,

Conflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.

Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates Jeffrey F. Krane, MD PhD Associate Professor of Pathology Harvard Medical School Chief, Head and Neck Pathology Service Associate Director,

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility

Thyroid Cancer. What is cancer?

What is cancer? Thyroid Cancer The body is made up of hundreds of millions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly fashion. During the early years of a

Thyroid FNA Ancillary Studies. Douglas P. Clark, M.D. Zubair W. Baloch, M.D., Ph.D.

Thyroid FNA Ancillary Studies Douglas P. Clark, M.D. Zubair W. Baloch, M.D., Ph.D. What are the goals of ancillary studies of thyroid FNAs? Characterization of a known malignancy (

Utility of flow cytometric κ and λ light chain analysis of peripheral blood

JBUON 2015; 20(5): 1322-1326 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Utility of flow cytometric κ and λ light chain analysis of peripheral

Molecular Diagnostics in Thyroid Cancer

Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金

Policy Wording. Together, all the way.

Cancer cover Policy Wording Together, all the way. Cancer Cover Insurance Policy Wording 1. Introducing your Policy 2. What is Cancer Cover Insurance? 3. About your Policy 4. Some terms defined 5. What

Lung Cancer. Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine

Lung Cancer Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine Alexandria, Egypt July 1-1 3, 2008 OBJECTIVES Describe and

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms Dr. Douaa Mohammed Sayed Small lymphocytic lymphoma/b-cell chronic lymphocytic leukemia BMB: nodular, interstitial, diffuse or a combination

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? Which test should be submitted? The answer to this depends on the clinical signs, and the diagnostic question you are asking. If

Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic

Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells

Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer

Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer Version History Version Date Summary of Change/Process 0.1 09.01.11

Benign (beh-nine): Not cancerous. Benign tumors may grow larger but do not spread to other parts of the body.

Cancer Glossary Source: National Cancer Institute: What You Need to Know About Cancer Adenoma (ad-in-oh-ma): A noncancerous tumor. Adjuvant therapy (AD-joo-vant): Treatment given after the primary treatment

Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach

Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach Publishing Team Erik Tanck (production manager/designer) Joshua Weikersheimer (publisher) Copyright 2006 by the American Society

Non neoplasticneoplastic condictions. Dipartimento di Scienze Biomorfologiche e Funzionali, Università di Napoli, Federico II Naples, Italy

European Federation of Cytology Societies 4tu Annual Tutorial in Cytopathology Trieste, June 6-10, 2011 Fine needle cytology of lymph nodes: Non neoplasticneoplastic condictions Pio Zeppa MD PhD Pio Zeppa